cliffwatch

glycopyrronium tosylate · Journey · NDA 210361

Qbrexza

Earliest generic entry, as listed
28 Feb 2033

Blocked by patent: US 10004717, US 10543192, US 10548875, US 8859610, US 9259414.

Listed patents · 8 unexpired

PatentClaimsExpires
US 10004717product, use U-239828 Feb 2033
US 10543192product28 Feb 2033
US 10548875substance, product, use U-239828 Feb 2033
US 8859610product, use U-239828 Feb 2033
US 9259414use U-239828 Feb 2033
US 9744105product, use U-239818 Jul 2030
US 8618160product, use U-239810 Dec 2029
US 10052267product, use U-239817 Oct 2028

Exclusivities · 0 unexpired

No unexpired exclusivities listed.

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

  • 25 Oct 2026First generic approved · 210361-001
  • 25 Oct 2026Generic approved · 210361-001

Products covered · 1

NDA · productFormStrengthListed expiry
210361 · 001 · RLDcloth, topicalEQ 2.4% BASE28 Feb 2033